Stock Analiz

Q32 Bio Inc. QTTB

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$8.71Market cap $261M
Open the interactive analysis →

Q32 Bio Inc. (QTTB) is a healthcare company listed in the US with a market value of about $261M. In the twelve months to September 30, 2026 it had revenue of $54M and net income of $32M, a net margin of 60.0%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is shareholder returns (0/5).

Key numbers: a P/E of 2.5, 5-year revenue growth of 82% a year, a 5-year average ROIC of -123%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 59% below the current price.

About Q32 Bio

Q32 Bio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $5M in 2018 to $54M in 2025, growth of about 39.1% a year. It was profitable in 1 of the last 9 years in our data. Its share count rose by 3455% over three years (dilution for shareholders). It spends 36% of revenue on research and development.

Score: 2.0 / 5

Value2/5
Future growth3/5
Track record2/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)2.5
Forward P/E—
P/FCF—
P/S4.9
P/B0.9
EV/EBITDA-1.3
PEG—
Dividend yield0.00%
FCF yield-7.7%
Shareholder yield0.0%
Intrinsic value vs. price−59%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)81.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1257.9%
ROIC (5-yr avg.)-122.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$54M$54M$0$1M$3M$34M$3M$2M$5M—
Net income$32M$30M-$48M-$54M-$5M-$96M-$129M-$104M-$56M-$30M
Free cash flow-$20M-$34M-$68M-$19M-$115M-$112M-$98M-$113M-$68M$5M
EPS (diluted)$3.47$2.42$-6.58$-153.96$-14.91$-286.64$-463.92$-409.25$-323.09$-2004.82
Net margin60.0%55.5%—-4649.0%-156.0%-281.9%-4762.9%-6237.4%-1044.3%—
ROIC—29.5%-347.7%——-49.6%-48.7%-33.3%-24.1%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $39.67, 355% above the current price; targets range from $29.00 to $59.00; the consensus rating is “Strong buy”; expected EPS is $-1.40 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Q32 Bio’s P/E ratio?

About 2.5, based on the last twelve months of diluted earnings per share.

Is Q32 Bio stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 59% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Q32 Bio pay a dividend?

Not currently.

Is Q32 Bio a good stock to buy?

We do not give buy or sell advice. Q32 Bio scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.